Patents by Inventor Philippe Horellou

Philippe Horellou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)
    Publication number: 20050069523
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic factor (GDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: July 9, 2003
    Publication date: March 31, 2005
    Inventors: Philippe Horellou, Jacques Mallet, Michel Perricaudet, Frederic Revah, Emmanuelle Vigne
  • Genetically-modified neural progenitors and uses thereof
    Publication number: 20040009592
    Abstract: The invention concerns human neural progenitor cells containing introduced genetic material encoding a product of interest, and their use for the treatment of neurodegenerative diseases.
    Type: Application
    Filed: November 27, 2002
    Publication date: January 15, 2004
    Applicant: Rhone-Poulenc Rorer S.A.
    Inventors: Olivier Sabate, Philippe Horellou, Marie-Helene Buc-Caron, Jacques Mallet
  • RECOMBINANT ADENOVIRUSES CODING FOR GLIAL-DERIVED CELL NEUROTROPHIC FACTOR (GDNF)
    Publication number: 20020031493
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic factor (GDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: August 1, 1997
    Publication date: March 14, 2002
    Applicant: RHONE-POULENC RORER S.A.
    Inventors: PHILIPPE HORELLOU, JACQUES MALLET, MICHEL PERRICAUDET, FREDERIC REVAH, EMMANUELLE VIGNE
  • RECOMBINANT VIRUSES CODING FOR A GLUTAMATE DECARBOXYLASE (GAD) ACTIVITY
    Publication number: 20020028212
    Abstract: Recombinant viruses comprising a heterologous DNA sequence coding for a protein having glutamate decarboxylase (GAD) activity, preparation thereof, and therapeutic use thereof, in particular for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: November 5, 1996
    Publication date: March 7, 2002
    Inventors: MARIE-CLAUDE GEOFFROY, PHILIPPE HORELLOU, JEAN-FRANCOIS JULIEN, JACQUES MALLET, MICHEL PERRICAUDET, JEAN-JACQUES ROBERT, EMMANUELLE VIGNE, ALEXIS BEMELMANS
  • GENETICALLY-MODIFIED NEURAL PROGENITORS AND USES THEREOF
    Publication number: 20020006660
    Abstract: The invention concerns human neural progenitor cells containing introduced genetic material encoding a product of interest, and their use for the treatment of neurodegenerative diseases.
    Type: Application
    Filed: February 28, 1997
    Publication date: January 17, 2002
    Applicant: Rhone-Poulenc Rorer, S.A.
    Inventors: OLIVIER SABATE, PHILIPPE HORELLOU, MARIE-HELENE BUC-CARON, JACQUES MALLET
  • Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF)
    Patent number: 6245330
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic growth factor (GDNF) are provided. The recombinant adenoviruses are useful in a method of expressing GDNF in a cell, wherein the cell is present in a mammal suffering from Parkinson's disease, comprising infecting said cell with a replication-defective recombinant adenovirus comprising a DNA sequence encoding GDNF operably linked to a promoter by administering the adenovirus into cells of the central nervous system. The recombinant adenoviruses of the invention are also useful in a method of treating Parkinson's disease comprising administering into cells of the central nervous system of a mammal suffering therefrom a replication defective recombinant adenovirus comprising ITRs, an encapsidation sequence and a DNA sequence encoding GDNF operably linked to a promoter, wherein the adenovirus E1 gene is non-functional and GDNF is expressed at a level that provides a therapeutic effect.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: June 12, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Philippe Horellou, Jacques Mallet, Michel Perricaudet, Frédéric Revah, Emmanuelle Vigne